I-MAB News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

28.01.22	I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs (PR Newswire)
18.01.22	I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors (PR Newswire)
14.01.22	I-Mab Announces Execution of Senior Management Team Share Purchase Plan (PR Newswire)
12.01.22	I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors (PR Newswire)
06.01.22	I-Mab Announces Senior Management Team Share Purchase Plan (PR Newswire)
31.12.21	I-Mab Announces Upcoming Participation at January Conferences (PR Newswire)
27.12.21	I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors (PR Newswire)
20.12.21	I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization (PR Newswire)
15.12.21	I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China (PR Newswire)
15.12.21	Pre-market Movers: IDRA, GRTX, SEAC, ALZN, SIDU… (RTTNews)
14.12.21	I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021 (PR Newswire)
09.12.21	I-Mab to Hold Investor Call to Present In-depth Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma (PR Newswire)
08.12.21	I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease (PR Newswire)
07.12.21	I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited (PR Newswire)
03.12.21	I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors (PR Newswire)
10.11.21	I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa (PR Newswire)
09.11.21	I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC (PR Newswire)
08.11.21	I-Mab and Roche Diagnostics Announce Strategic Collaboration to Co-Develop Companion Diagnostics Solutions for I-Mab's Innovative Pipeline at the 4th CIIE (PR Newswire)
04.11.21	I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma at ASH 2021 (PR Newswire)
03.11.21	I-Mab Announces Upcoming Participation at November Conferences (PR Newswire)
01.11.21	I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer Appointments (PR Newswire)
26.10.21	I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its Innovative Assets in China (PR Newswire)
22.10.21	I-Mab Expands U.S. Footprint with New R&D Site in San Diego (PR Newswire)
18.10.21	I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China (PR Newswire)
13.10.21	I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China (PR Newswire)
05.10.21	I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting (PR Newswire)
01.10.21	I-Mab Announces Upcoming Participation at October Conferences (PR Newswire)
30.09.21	I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab (PR Newswire)
28.09.21	I-Mab Reports Acceptance Of IND Application In China For Phase 2 Trial With Enoblituzumab (RTTNews)
28.09.21	I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors (PR Newswire)
13.09.21	I-Mab Added to FTSE ESG Index Series (PR Newswire)
02.09.21	I-Mab Added to FTSE Russell Global Equity Index Series (PR Newswire)
31.08.21	I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021 (PR Newswire)
30.08.21	I-Mab Announces Upcoming Participation at September Conferences (PR Newswire)
19.08.21	I-Mab Announces Establishment of Environmental, Social and Governance Committee (PR Newswire)
17.08.21	I-Mab to Provide Business and Corporate Updates and Report Financial Results for the Six Months Ended June 30, 2021 on August 31, 2021 (PR Newswire)
11.08.21	I-Mab Reports Positive Data Of Plonmarlimab On Treatment Of CRS In Patients With Severe COVID-19 (RTTNews)
11.08.21	I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe COVID-19 (PR Newswire)
30.07.21	I-Mab : FDA Oks IND To Initiate Phase 1 Study For Protollin For Treatment Of Alzheimer's Disease (RTTNews)
30.07.21	I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease (PR Newswire)
29.07.21	I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million (PR Newswire)
28.07.21	I-Mab : China Accepts IND For Phase 2 Trial Of Efineptakin Alfa In Combination With PD-1 Therapy (RTTNews)
28.07.21	I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China (PR Newswire)
27.07.21	I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange (PR Newswire)
09.07.21	I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms (PR Newswire)
01.07.21	I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio (PR Newswire)
30.06.21	I-Mab Honored with Top Rankings by Institutional Investor (PR Newswire)
29.06.21	I-Mab Announces Upcoming Participation at July Conference (PR Newswire)
25.06.21	I-Mab : China Approves Phase 1b Trial Of Felzartamab In Systemic Lupus Erythematosus (RTTNews)
25.06.21	I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu I-MAB (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten